In Immunology, J&J Makes A Big Move On Biologic Combinations
The company has initiated a Phase II study of Tremfya and Simponi in combination for the treatment of ulcerative colitis, J&J's first human study of two targeted immunology drugs together.
You may also be interested in...
The company reported positive Phase II results and will move its potential fourth-to-market IL-23 inhibitor into Phase III in Crohn's disease later this year. Mirikizumab – in Phase III for psoriasis and ulcerative colitis – may be the second IL-23 drug for an IBD indication.
The company outlined pharma growth drivers, including 14 currently marketed medicines that will achieve $1bn or more in sales by 2020 and 10 new filings through 2023.
The pandemic has reignited interest and investment in vaccines across a wide array of disease areas by big pharma and venture investors, a panel of BIO experts said.